AstraZeneca’s Drug Shows Promise For Resistant Hypertension In Phase 3 Trial BY Vandana Singh • July 14, 2025July 14, 2025 AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension. The trial included patients[...] Read more
